Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-06-20T01:23:59.420Z Has data issue: false hasContentIssue false
  • English
  • Français

Remisión sintomática y funcionamiento social/profesional en pacientes con esquizofrenia tratados ambulatoriamente: prevalencia y asociaciones en un estudio transversal

Published online by Cambridge University Press:  12 May 2020

Luis San ,
Antonio Ciudad ,
Enrique Álvarez ,
Julio Bobes  and
Inmaculada Gilaberte
Luis San
Affiliation:
Hospital San Rafael, Barcelona, España
Antonio Ciudad
Affiliation:
Laboratorios de Investigación Lilly S.A., Avda. de la Industria 30, 28108Alcobendas, Madrid, España
Enrique Álvarez
Affiliation:
Departamento de Psiquiatría, Hospital de Sant Pau, UAB, REM-TAP, Barcelona, España
Julio Bobes
Affiliation:
Área de Psiquiatría, Facultad de Medicina, Universidad de Oviedo, Oviedo, España
Inmaculada Gilaberte
Affiliation:
Laboratorios de Investigación Lilly S.A., Avda. de la Industria 30, 28108Alcobendas, Madrid, España
Get access

Resumen

Objetivo.

El progreso de las opciones terapéuticas para la esquizofrenia ha reavivado las expectativas a largo plazo de investigadores, médicos y pacientes. Actualmente, en las definiciones de resultado terapéutico se incluyen la remisión mantenida de los síntomas y el funcionamiento adecuado en un marco conceptual, siendo la recuperación del paciente el propósito final. Nuestro objetivo fue conocer la prevalencia y los rasgos clínicos de los pacientes con esquizofrenia que consiguen estos resultados.

Métodos.

Se hizo un estudio multicéntrico y transversal en más de 100 centros de salud mental de España. Para evaluar los resultados se usaron los criterios publicados recientemente sobre la remisión sintomática basados en acuerdos operativos generales y en la escala de Evaluación Global del Funcionamiento. También se evaluaron otros aspectos clínicos, como los síntomas depresivos, la cognición social, el ajuste premórbido y las actitudes de los pacientes frente a la medicación.

Resultados.

Se analizaron los datos de 1.010 pacientes. De estos, 452 (44,8%) estaban en remisión clínica, pero sólo 103 (10,2%) tenían un funcionamiento social y/o profesional adecuado. Los factores que predicen ambos resultados son mejor ajuste premórbido (cociente de probabilidad, CP = 1,56) y mejor función cognitiva social (CP = 1,14). Otros factores, como la aceptación del tratamiento, la psicoterapia actual o pasada y la edad del paciente, no se asociaron a la funcionalidad, sino sólo a la remisión clínica. El abuso actual de sustancias y la rehabilitación anterior se asociaron a una probabilidad menor de remisión sintomática.

Conclusión.

Aunque la remisión de los síntomas en pacientes con esquizofrenia es un objetivo realista y accesible, deberían realizarse esfuerzos en el futuro para conseguir un funcionamiento prolongado adecuado en estos pacientes.

Keywords

EsquizofreniaRemisiónRecuperaciónEstudios transversales
Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 15 , Issue 2 , March 2008 , pp. 65 - 74
Copyright
Copyright © European Psychiatric Association 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Alvarez, E, Ciudad, A, Olivares, JM, Bousono, M, Gomez, JC. Randomized A: A 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol 2006;26:238–49.Google ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.Google Scholar
Andreasen, NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 1982;39:784–8.CrossRefGoogle ScholarPubMed
Andreasen, NC. Positive vs. negative schizophrenia: a critical evaluation. Schizophr Bull 1985;11:380–9.CrossRefGoogle ScholarPubMed
Andreasen, NC, Carpenter, WT Jr, Kane, JM, Lasser, RA, Marder, SR, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441–9.CrossRefGoogle ScholarPubMed
Andreasen, NC, Olsen, S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982;39:789–94.CrossRefGoogle Scholar
Birchwood, M, Mason, R, MacMillan, F, Healy, J. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med 1993;23:387–95.CrossRefGoogle ScholarPubMed
Cannon-Spoor, HE, Potkin, SG, Wyatt, RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982;8:470–84.CrossRefGoogle ScholarPubMed
Ciudad, A, Prieto, L, Olivares, JM, Montejo, AL, Ros, S, Novick, D. The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample. Actas Esp Psiquiatr 2004;32:227–35.Google ScholarPubMed
Docherty, JP, Bossie, CA, Lachaux, B, Bouhours, P, Zhu, Y, Lasser, R, et al. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol 2007;22:51–5.Google Scholar
Emsley, R, Oosthuizen, PP, Kidd, M, Koen, L, Niehaus, DJ, Turner, HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006;67:1707–12.CrossRefGoogle ScholarPubMed
Emsley, R, Rabinowitz, J, Medori, R. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007;89:129–39.CrossRefGoogle ScholarPubMed
Helldin, L, Kane, JM, Karilampi, U, Norlander, T, Archer, T. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res 2006;40:738–45.CrossRefGoogle Scholar
Hogan, TP, Awad, AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992;22:347–52.CrossRefGoogle ScholarPubMed
Kohler, CG, Lallart, EA. Postpsychotic depression in schizophrenia patients. Curr Psychiatry Rep 2002;4:273–8.CrossRefGoogle ScholarPubMed
Lambert, M, Schimmelmann, BG, Naber, D, Schacht, A, Karow, A, Wagner, T, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006;67:1690–7.CrossRefGoogle ScholarPubMed
Lasser, RA, Bossie, CA, Gharabawi, GM, Kane, JM. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005;77:215–27.CrossRefGoogle ScholarPubMed
Leucht, S, Lasser, R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006;39:161–70.CrossRefGoogle Scholar
Liberman, RP, Kopelowicz, A. Recovery from schizophrenia: a challenge for the 21 st century. Int Rev Psychiatry 2002;14:245–55.CrossRefGoogle Scholar
Liberman, RP, Kopelowicz, A, Ventura, J, Gutkind, D. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry 2002;14:256–72.CrossRefGoogle Scholar
Lopez-Garcia, E, Banegas, JR, Graciani Perez-Regadera, A, Gutierrez-Fisac, JL, Alonso, J, Rodriguez-Artalejo, F. Population-based reference values for the Spanish version of the SF-36 Health Survey in the elderly. Med Clin (Barc) 2003;120:568–73.Google ScholarPubMed
Lublin, H, Eberhard, J, Levander, S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005;20:183–98.CrossRefGoogle ScholarPubMed
Mandel, MR, Severe, JB, Schooler, NR, Gelenberg, AJ, Mieske, M. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Arch Gen Psychiatry 1982;39:197–203.CrossRefGoogle ScholarPubMed
Ott, SL, Spinelli, S, Rock, D, Roberts, S, Amminger, GP, Erlenmeyer-Kimling, L. The New York High-Risk Project: social and general intelligence in children at risk for schizophrenia. Schizophr Res 1998;31:1–11.CrossRefGoogle ScholarPubMed
Perkins, D, Lieberman, J, Gu, H, Tohen, M, McEvoy, J, Green, A, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004;185:18–24.CrossRefGoogle ScholarPubMed
Robinson, DG, Woerner, MG, McMeniman, M, Mendelowitz, A, Bilder, RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:473–9.CrossRefGoogle ScholarPubMed
Rosenheck, RA, Leslie, DL, Sindelar, J, Miller, EA, Lin, H, Stroup, TS, et al. Cost-effectiveness of second-generadon antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080–9.CrossRefGoogle Scholar
Sanjuan, J, Prieto, L, Olivares, JM, Ros, S, Montejo, A, Ferrer, F, et al. GEOPTE Scale of social cognition for psychosis. Actas Esp Psiquiatr 2003;31:120–8.Google Scholar
Strauss, JS, Carpenter, WT Jr. The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia. Arch Gen Psychiatry 1974;31:37–42.CrossRefGoogle ScholarPubMed
Swartz, MS, Perkins, DO, Stroup, TS, Davis, SM, Capuano, G, Rosenheck, RA, et al. Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. Am J Psychiatry 2007;164:428–36.CrossRefGoogle ScholarPubMed
Swartz, MS, Wagner, HR, Swanson, JW, Stroup, TS, McEvoy, JP, McGee, M, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv 2006;57:1110–6.CrossRefGoogle ScholarPubMed
van Mastrigt, S, Addington, J. Assessment of premorbid function in firstepisode schizophrenia: modifications to the Premorbid Adjustment Scale. J Psychiatry Neurosci 2002;27:92–101.Google Scholar
van Os, J, Burns, T, Cavallaro, R, Leucht, S, Peuskens, J, Helldin, L, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006;113:91–5.Google Scholar
van Os, J, Drukker, M, a Campo, J, Meijer, J, Bak, M, Delespaul, R. Validation of remission criterio for schizophrenia. Am J Psychiatry 2006;163:2000–2.CrossRefGoogle Scholar
Ware, J Jr, Kosinski, M, Keller, SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–33.CrossRefGoogle ScholarPubMed
Zimmerman, M, Posternak, MA, Chelminski, I. Defining remission on the Montgomery-Asberg depression rating scale. J Clin Psychiatry 2004;65:163–8.CrossRefGoogle ScholarPubMed